Clinical trials
catalyst calendar across sponsors →Studies where ABOS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 10 tracked-famous managers (Hudson Bay Capital Management LP, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MILLENNIUM MANAGEMENT LLC, +5 more) · FINRA short interest 9.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 4 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) ScoreRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: sabirnetug, Placebo | Alzheimer Disease | 542 | Oct 2026 | ≤ 73 d | 2025-10-27 |
| A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy ParticipantsNCT06511570Estimate blood levels of sabirnetug (ACU193)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: sabirnetug (ACU193) · Combination product: Sabirnetug + rHuPH20 | Alzheimer Disease | 28 | 2024-09-17actual | — | 2024-10-18 |
| A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild ADNCT04931459Incidence and Nature of Treatment-Related Adverse Events (AE) or Serious Adverse Events (SAE) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ACU193, Placebo | Alzheimer Disease | 65 | 2023-06-12actual | — | 2023-07-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19